Oral and poster presentations span three priority programs in breast, gynecologic, and gastrointestinal cancers, advancing rapidly toward pivotal development Company to...
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapy ...
These mutual funds are the crème de la crème of their respective investment categories.
TEVIMBRA plus ZIIHERA and chemotherapy demonstrated statistically significant overall survival benefit with an unprecedented seven-month improvement in first-line HER2+ GEA ...
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026,...
Long-term and real-world evidence reinforce BRUKINSA as the foundation of CLL treatment Three oral presentations at ASCO highlight rapid acceleration of BeOne’s solid...
Campaign connects the preparation, precision, and grit that define great goalkeeping to the persistent scientific, clinical, and community efforts that drive progress in cancer care ...
BEQALZI is a foundational BCL2 inhibitor designed for greater potency and selectivity, with potential to improve efficacy, tolerability, and convenience versus others in the class ...
Total global revenues of $1.5 billion for the first quarter, an increase of 35% from the prior year ...
Barchart Research What to Expect from ONC Earnings ONC Generated May 5, 2026 Current Price $297.49 EPS Estimate $$0.73 Consensus Rating Strong Buy Average Move 4.66% BeOne Medicines Delivers Quarterly...